title: Chronic lithium treatment decreases brain phospholipase A2 activity.
abstract: Chronic lithium administration decreases the turnover of arachidonic acid (AA) in several brain phospholipids. This suggests that lithium may attenuate phospholipase A2 (PLA2) activity in brain. We now report effects of chronic lithium treatment on PLA2 activity in postnuclear supernatant from rat brain: Enzyme activity was determined by two assay methods, radiometric and fluorometric, and measured the release of the fatty acid on the second acyl position (sn2) from choline and ethanolamine phospholipids. PLA2 activity in brain postnuclear supernatant from rats chronically treated with lithium in the diet was significantly decreased (20-50%) when compared with controls. In vehicle or lithium-treated rats, PLA2 activity was not significantly augmented or attenuated by the addition of calcium chelators, divalent cations or LiCl supplementation (1.0 mM) to postnuclear supernatant. These results suggest that a major therapeutic effect of lithium is to attenuate brain PLA2 activity involved in signal transduction.
authors.affiliation: Laboratory of Neurosciences, National Institute on Aging, Bethesda, MD 20892-1582, USA. mcjchang@box-m.nih.gov
authors.forename: M C
authors.initials: MC
authors.lastname: Chang
authors.forename: C R
authors.initials: CR
authors.lastname: Jones
mesh_terms: D000818:Animals; D018692:Antimanic Agents / Q000494:pharmacology*; D001921:Brain / Q000187:drug effects* / Q000201:enzymology; D002614:Chelating Agents / Q000494:pharmacology; D004533:Egtazic Acid / Q000494:pharmacology; D004791:Enzyme Inhibitors / Q000494:pharmacology*; D005470:Fluorometry; D018021:Lithium Chloride / Q000494:pharmacology*; D015636:Magnesium Chloride / Q000494:pharmacology; D008297:Male; D010713:Phosphatidylcholines / Q000378:metabolism; D010714:Phosphatidylethanolamines / Q000378:metabolism; D010741:Phospholipases A / Q000037:antagonists & inhibitors*; D054467:Phospholipases A2; D051381:Rats; D011916:Rats, Inbred F344
chemical_list: D018692:Antimanic Agents; D002614:Chelating Agents; D004791:Enzyme Inhibitors; D010713:Phosphatidylcholines; D010714:Phosphatidylethanolamines; D015636:Magnesium Chloride; D004533:Egtazic Acid; D010741:Phospholipases A; D054467:Phospholipases A2; D018021:Lithium Chloride